FORM PTO-1449

MAY 1 2 2003

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

U.S. Dept. of Commerce Patent and Trademark Office Atty Docket No. Serial No. P3121R1 09/964,994

Applicant

Audrey Goddard et al.

Filing Date 26 Sep 2001 Group 1646

U.S. PATENT DOCUMENTS

Examine	or			TOTAL POCOMENTS			
nitials		Document Number	Date	Name	Class	Subclass	Filing Data
	1	4,179,337	18.12.79	Davis et al.	01000		Filing Date
	$\frac{2}{2}$	4,275,149	23.06.81	Litman et al.		BEC	EIVED
•	3	4,301,144	17.11.81	Iwashita et al.			KIVEN
	4	4,496,689	29.01.85	Mitra, G.		MAY	1
	5	4,640,835	03.02.87	Shimizu et al.			
	6	4,657,760	14.05.87	Kung et al.		CH CENT	
	7	4,670,417	02.06.87	Iwasaki et al.		. OLIVIE	R 1600/2900
	8	4,676,980	30.06.87	Segal et al.			'
	9	4,736,866	12.04.88	Leder et al.		ļ	-
,	10	4,791,192	13.12.88	Nakagawa et al.			
	11	4,816,567	28.03.89	Cabilly et al Dufl	(1)	-9	
	12	4,870,009	26.09.89	Evans et al.	CATI	· •	
	13	5,206,344	27.04.93	Katre et al.	[İ
	14	5,225,212	06.07.94	Martin et al.			
	15	5,364,934	15.11	Drayna et al.	İ		-
		5,536,637	16.07.96	Jacobs, K.			
	17	5,545,806	13.08.96	Lonberg et al.			1
	- 1	5,545,807	13.08.96	Surani et al.		1	
	ī	5,569,825	29.10.96	Lonberg et al.	\		
	X	5 625,126	29.04.97	Lonberg et al.			
,		5,633,425	The state of the s	Lonberg et al.		\downarrow	_
		5,654,010	05.08.97	Johnson et al.		l	
	23	5,661,016	26.08.97	Lonberg et al.			

FOREIGN PATENT DOCUMENTS

Examiner nitials		Document Number	Dete	TOREIGN PATENT DOCUMENTS		T .	Transl	ation
			Date	Country	Class	Subclass	Yes	
COZ	24	3089	25.07.79	EP (ENGLISH CLAIMS)		Cubciass	165	No
1	25	404,097	27.12.90	EP (ENGLISH ABSTRACT ATTACHED)		1	l	
- 1 - 1	26	WO 90/13641	15.11.90	PCT		1		
	27	WO 91/00360	10.01.91	PCT		·		
1	28	WO 92/20373	26.11.92	PCT	1			
11	29	WO 93/08829	13.05.93	PCT		\times		
11	30	WO 93/11161	10.06.93	PCT				
$1 \perp$	31	WO 96/07399	14.03.96	PCT				
	32	WO 96/27011	06.09.96	PCT				
	33	WO 96/40072	19.12.96	PCT	1/1	1	1	
aminer					-//			`
	P	Kenme	111	Date Co	onsidered /5	14/2		

Cemmeus

6/30/03 *Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. Dept. of Commerce Atty Docket No. P3121R1 Patent and Trademark Office LIST OF DISCLOSURES CITED BY PLICANT Applicant Audrey Goddard et al. MAY (Use several sheets if necessary Filing Date Group 26 Sep 2001 /EC FOREIGN PATENT DOCUMENTS Examiner Initials Document Number Date Translation Country Class Subclass COF Yes No WO 97/03692 06.02.97 PCT 35 WO 97/33551 18.09.97 PCT OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.) Altschul and Gish, "Local Alignment Statistics" Methods in Enzymology 266:460-480 (1996) 36 Altschul et al., "Gapped BLAST and PSI-BLAST: A New Generation of Protein Database Search Programs' Nucleic Acids Research. 25(17):3389-3402 (1997) Andarson, W.F., "Human Gene Therapy." <u>Science.</u> 256(5058):808-813 (May 8, 1992) 38 Beal and Darvan, "Second Structural Motif for Recognition of DNA by Oligonucleotide-Directed Triple-Helix Formation" Science 251:1360-1363 (1991) 39 BLAST Results A-- A-6 (Dayhoff) 40 BLAST Results B-1 - B-4 (GenBank) 41 Boerner et al., "Production of Antigen-Specific Human Monoclonal Splenocytes" The Journal of Immunology 147(1):86-95 (199 Antibodies From In Vitro-Primed Human Bradley, "Production and Analysis of Chimaeric Mice" Teratoricomas and Embryonic Stem Cells: A Practical Approach, E. J. Robertson, ed. 43 IRL, Oxford, Chapter 5, pps. 113-151 (1987) Brennan et al., "Preparation of bispecific artibodies by chemical recombination of monoclonal immunoglobulin G1 fragments" Science 229:81-83 (1) 1985) Brodeur et al., "Mouse-Human Myeloma Partners for the Production of Heterohybridomas" Monoclonal Antibody Production Techniques and Applaichtions, New York:Marcel Dekker, Inc. pps. 51-63 (1987) Caron et al., "Engineered Humanized Dimeric Forms of IgG are More Effective Antibodies." Journal of Experimental Medicine. 176(4):1101 46 Carter et al., "Improved Oligon cleatide Site-Directed Mutagenesis Using M13 Vectors" Nucl. Acids Res. 13(12):4431-4443 (June 25) 47 Chevray and Nathans, Protein Interaction Cloning in Yeast: Identification of Mammalian Proteins That React With the Leucine Zipper of Jun" Proc. Natl. Acad. Sci. USA 89:5789 5793 (July 1992) "The Two-Hybrid System: A Method to Identify and Clone Genes for Proteins that Interact with a Protein of Interest." Proc. Natl. Acad. Sci. USA 88:9578-9582 (1991) The Nature of the Accessible and Buried Surfaces in Proteins" Journal Mo Chothia, (1976) 50 Biol. 105:1-12

Teland., "Design and Production of Single Immunization Vaccines Using Polylactide Polygycolide Microsphere Systems." Vaccine Design: The Subunit and Adjuvant Approach, Powell and Newman, New York:Plenum Press pps. 439-462 (1995) Cohen, Jack S. ed. Oligodeoxynucleotides: Antisense Inhibitors of Gene Expression, Boca Raton

Examiner enner

Press, Inc. (1989)

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Kohler and Milstein., "Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity."

Date Considered

mmercy *Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Nature. 256:495-497 (August 7, 1975)

Examiner

FORM PTO-1449

U.S. Dept. of Commerce Patent and Trademark Office

Atty Docket No. P3121R1

26 Sep 2001

Serial No.

Applicant

Audrey Goddard et al. Filing Date

al. MAY
Group 15 2003

ECHTED 10001000

ENTA TRAD LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

73	Immunology 148(5):1547-1553 (1992)	
74	Kozbor et al., "A Human Hybrid Myeloma for Production of Human Monoclonal Antibodies" The Journal of	_

ee et al., "Complexes Formed by (Pyrimidine) $_{
m n}$ (purine) $_{
m n}$ DNAs on Lowering the pH are Three-Stranded. 75

"Controlled release of bioactive agents from lactide/glycolide polymers" Biodegradable Polymers Delivery Systems, M. Chasin and R Langer, New York: Marcel Dekker pps. 1-41 (1990) as Drug 76

"Targeted Mutation of the DNA Methyltransferase Gene Results in Embryonic Lethality." Cell. Li et al., 69:915-926

Lonberg and Huszar., "Human Antibodies From Transgenic Mice" International 13(1):65-93 (1995) Reviews of Immunology 78

Lonberg et al., "Antigen-Specific Human Antibodies From Mice Comprising Four Distinct Genetic Modifications " Nature 368(6474):856-859 (Apr 28, 1994)

Lutz-Freyermuth et al., Couantitative Determination That One of Two Potential RNA-binding Domains A Protein Component of the U1 Small Nuclear Ribonucleoprotein Complex Binds with High Affinity to of Two Potential RNA-binding Domains of the Natl. Acad. Sci. USA 8/1693-6317 (1990) acellular expression, And activity of a human anti-human immunodeficiency Marasco et al., "Design, intracellular expression, and

virus type 1 gp 120 single-charo antibody" <u>Proc.</u> ad. Sci. USA 90:7889-7893 (1993)

Marks et al., "By-Passing Immunization: Building righ Affinity Human Antibodies by Chain Shuffling" Bio/Technology 10:779-783 (1992)

Marks et al., "By-Passing Immunization: Human Antibodies From V-gene Libraries Displayed On Phage" Mol. Biol. 222:581-597 (1991) 83

Martin et al., "GAP Domains Responsible for Ras p21-Dependent Inhibition of Muscarinic Atrial K+ Channel Currents" <u>Science</u> 255:192-194 (1

Merrifield, R.B., "Solid Phase de Synthesis. V. The Synthesis of a Tetrapeptide" J. Am. Chem. Soc. epţ 85(14):2149-2154 (Jul 1963) 85

Milstein and Cuello, "Hypridomas and Their Use in Immunohistochemistry" Nature 305:537-540 (Oct 1983) 86

Mordenti et al., "The Use of Interspecies Scaling in Toxicokinetics" Toxicokinetics and New Drug Development, Yacobi et al., eds., New York: Pergamon Press pps 42-96 (1989) 87

Morrison, Immunology: Success in Specification Nature. 368 (6474):812-813 (Apr 28, 1994)

Munson and Rodbard, "LIGAND: A Versatile Computerized Approach for Characterization of Ligand-Binding Systems Analytical Biochemistry 107:220-239 (1980)

Newberger, M., "Generating High-Avidity Human Mabs in Mice" Nature Biotechnology. 14(7):826 (Jul 1996) 90

Nielsen et al., "Identification of Prokaryotic and Eukaryotic Signal Peptides and Prediction of Their Cleavage Sites" Protein Engineering. 10(1):1-6 (1997)

Nygren, H., "Conjugation of Horseradish Peroxidase to Fab Fragments with Different Homobifunctional and Heterobifunctional Cross-Linking Reagents" The Journal of Histochemistry and Cytochemistry 30(5):407-412

Examiner

mmen

Date Considered

FORM PTO-1449

99

MAY 1 2 2003

U.S. Dept. of Commerce

Atty Docket No.

Patent and Trademark Office

P3121R1 Applicant

Audrey Goddard et al.

LIST OF DISCLOSURESCITED BY

(Use several sheets if necessary)

Filing Date 26 Sep 2001

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.) Okano et al., "Myelin Basic Protein Gene and the Function of Antisense RNA in Its Repression

Myelin-Deficient Mutant Mouse." J. Neurochemistry. 56(2):560-567 (1991) Paborsky et al., "Mammalian Cell Transient Expression of Tissue Factor for the Production of Anxigen"

Protein Eng. 3(6):547-553 (1990)

Pain et al., "Preparation of Protein A-Peroxidase Monoconjugate Using a Heterobifunctional Reagent, and its Use in Enzyme Immunoassays" Journal of Immunological Methods 40:219-230 (1981)

Pluckthun., "Antibodies From Escherichia coli." The Pharmacology of Monoclonal Antibodies: Handbook of Experimental Pharmacology., Rosenberg and Moore, eds., Berlin:Springer-Verlag, Chapter 11, Vol. 96

Presta, L., "Antibody Engineering" Curr. Op. Struct. Biol. 2:593-596 (1992) 97

Riechmann et al., "Reshaping Human Antibodies for Therapy" Nature 332/23/327 (Mar 24, 1988) 98

Rossi, J.J., "Making Ribozymes Work in Cells." Current Biology. 471 (1994)

Sambrook et al. Molecular Cloning: A Laboratory Manual, Second edition, New York: Cold Spring Harbor *100 Laboratory Press (1989)

Shalaby et al., "Development of Humanized Bispecific Anylbodies Reactive with Cytotoxic Lymphocytes and Tumor Cells Overexpressing the HER2 Protooncogene" Jo of Experimental Medicine 175:217-225 (Jan 1,

Shopes, "A Genetically Engineered Human IgG Muhant with Enhanced Cytolytic Activity." Journal of Immunology. 148(9):2918-2922 (1992)

Skinner et al., "Use of the Glu-Glu-Phe C-Tyminal Epitope for Rapid Purification of the Catalytic Domain of Normal and Mutant ras GTPase-activating Proteins." J. Bio. Chem. 266:14163-14166 (1991)

Stein and Cohen., "Oligodeoxynucleonid as Inhibitors of Gene Expression: A Review." Cancer Research 48:2659-2668 (May 15, 1988) 104

Stevenson et al., "A Chimeria Antibody With Dual Fc Regions (biskabFc) Prepared by Manipulations at the IgG Hinge." Anti-Cancer Drug gign 3(4):219-230 (1989)

Stewart et al. Solid-Phase Reptide Synthesis, San Francisco, CA:W.H. Treeman Co. (1969) *106

Suresh et al., "Bispecific Monoclonal Antibodies from Hybrid Hybridomas" Methods in Enzymology 121:210-228 (1986) 107

Thomas and Capeochi, "Site-Directed Mutagenesis by Gene Targeting in Mouse Embryo Perived Stem Cells." Cell. 51:503-512 (Nov 1987)

"Hybridization of Denatured RNA and Small DNA Fragments Transferred to Nitrocellulose" Proc. Thomas, P/ Agad. Sci. USA 77(9):5201-5205 (September 1980)

Tranhecker et al., "Bispecific Single Chain Molecules (Janusins) Target Cytotoxic Lymphocytes on HIV Infected Cells" EMBO Journal 10(12):3655-3659 (1991) 110

Tutt et al., "Trispecific F(ab')3 Derivatives That Use Cooperative Signaling Via the TCR/CD3 Complex and CD2 to Activate and Redirect Resting Cytotoxic T Cells" J. Immunol. 147(1):60-69 (1991) (11

van der Krol et al., "Modulation of Eukaryotic Gene Expression by Complementary RNA or DNA Sequences." Biotechniques. 6(10):958-976 (1988)

Examiner

minu

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner

. . .

FORM PTO-1449

113

114

115

116

117

118

120

121

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

mmeus